Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes

Launched by SEOUL NATIONAL UNIVERSITY BUNDANG HOSPITAL · May 22, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a combination therapy using cilostazol and ginkgo biloba on cognitive function in older adults with type 2 diabetes. The goal is to see if this treatment can help improve thinking and memory skills, as people with diabetes are at a higher risk for cognitive decline and conditions like dementia. The study will involve adults aged 60 and older who have been diagnosed with type 2 diabetes and have a certain level of cognitive ability as measured by a brief mental assessment.

To participate, individuals must meet specific criteria, such as having controlled diabetes and a Mini-Mental State Examination score between 24 and 28, which indicates mild cognitive ability. However, those with other forms of diabetes, severe cognitive impairment, or certain health conditions may not be eligible. Participants will receive the study treatment and will be monitored for any changes in their cognitive function. This research could help pave the way for new ways to support brain health in people living with diabetes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with type 2 diabetes mellitus
• • Adults aged 60 years or older
• • Patients with a Mini-Mental State Examination (MMSE) score between 24 and 28 within the past 3 months
• Exclusion Criteria:
• • Patients with type 1 diabetes mellitus, diabetic ketoacidosis, or diabetic coma or precoma
• • Patients with poorly controlled blood glucose (HbA1c \> 10.0%)
• • Patients with an MMSE score below 24
• • Patients diagnosed with dementia (e.g., Alzheimer's disease)
• • Patients with suspected cognitive impairment due to other causes
• • Patients requiring antiplatelet or anticoagulant therapy other than the investigational product
• • Patients with thyroid dysfunction requiring treatment (i.e., abnormal TSH levels)
• • Patients with severe depression
• • Patients with severe infections, recent surgery (perioperative status), or major trauma
• • Patients with pituitary or adrenal insufficiency
• • Patients with other medical conditions requiring hospitalization
• • Patients with a history of alcohol or drug abuse within 1 year prior to screening
• • Patients with a history of taking medications that may affect cognitive function within 3 months prior to screening
• • Patients deemed by the investigator to be otherwise unsuitable for study participation